| NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
| NCT02016157 | Chronic Generalized Periodontitis | Drug: Moxifloxacin | Sri Hasanamba Dental College and Hospital | Phase 4 | 2011-09-01 | 2013-12-18 |
| NCT01302951 | Side-effect of Antibiotic | Drug: Moxifloxacin 400 mg | University Hospital, Saarland|Bayer | Phase 4 | 2008-07-01 | 2011-02-23 |
| NCT02595359 | Endophthalmitis | Drug: Moxifloxacin | Universidade Federal de Pernambuco | Phase 2 | 2013-01-01 | 2016-10-24 |
| NCT02770729 | Endophthalmitis | Drug: Moxifloxacin|Drug: No injection of moxifloxacin | University of Campinas, Brazil | Phase 3 | 2017-01-01 | 2017-03-15 |
| NCT01756521 | the Effect of Moxifloxacin on QT/QTc Interval | Drug: Moxifloxacin | Seoul National University Hospital|Korea National Enterprise for Clinical Trials|The Catholic University of Korea|Seoul National University Bundang Hospital | Phase 1 | 2013-01-01 | 2016-04-25 |
| NCT01876316 | Healthy | Drug: Moxifloxacin|Drug: Placebo | Inje University | | 2011-11-01 | 2013-06-11 |
| NCT00895089 | Liver Abscess | Drug: Moxifloxacin (Avelox)|Drug: ceftriaxone | Kaohsiung Veterans General Hospital.|Bayer | Phase 4 | 2009-05-01 | 2015-12-01 |
| NCT02322619 | Healthy | Drug: Moxifloxacin Tablets 400 mg | Dr. Reddy's Laboratories Limited | Phase 1 | 2012-11-01 | 2014-12-18 |
| NCT01055145 | TB | Drug: levofloxacin, moxifloxacin | Seoul National University Hospital | Phase 3 | 2010-03-01 | 2012-11-22 |
| NCT01603030 | Eye Infection/Inflammation Other | Drug: moxifloxacin 0,5% + prednisolone 1%|Drug: moxifloxacin/prednisolone combination | Adapt Produtos Oftalmolgicos Ltda. | Phase 3 | 2012-06-01 | 2012-05-21 |
| NCT01130922 | Gastric Bypass|Body Weight | Drug: moxifloxacin per IV|Drug: moxifloxacin per os | University Ghent | Phase 4 | 2010-03-01 | 2011-04-15 |
| NCT02176005 | Healthy | Device: DAV132|Drug: Moxifloxacin|Other: Negative Control | Da Volterra | Phase 1 | 2014-03-01 | 2016-02-03 |
| NCT01642485 | Effects of Different Meals on the QT/QTc Interval|Insulin and Oral Hypoglycemic [Antidiabetic] Drugs Causing Adverse Effects in Therapeutic Use|C-Peptide Effects on the QT/QTc Interval|Moxifloxacin ECG Profile in Fed and Fasted State|Japanese vs. Caucasian TQT Comparison | Drug: Moxifloxacin 400 mg fasted|Other: FDA breakfast|Other: Continental breakfast|Drug: Moxifloxacin 400 mg fed|Procedure: Insulin Clamp|Drug: Placebo | Richmond Pharmacology Limited | Phase 1 | 2011-07-01 | 2014-08-19 |
| NCT02531438 | Bacterial Pneumonia|Community-Acquired Infections | Drug: Omadacycline|Drug: Moxifloxacin | Paratek Pharmaceuticals Inc | Phase 3 | 2015-11-01 | 2017-01-24 |
| NCT00805558 | Chronic Periodontitis | Drug: moxifloxacin|Drug: Ciprofloxacin plus metronidazole | Facultad Nacional de Salud Publica|Universidad de Antioquia | Phase 4 | 2009-02-01 | 2010-05-10 |
| NCT00764582 | Corneal Transplantation | Drug: 1.5% levofloxacin ophthalmic solution|Drug: 0.5% moxifloxacin ophthalmic solution | Santen Inc.|Vistakon Pharmaceuticals | Phase 4 | 2008-09-01 | 2009-08-24 |
| NCT01653990 | QT Interval Prolongation | Drug: moxifloxacin|Drug: moxifloxacin-placebo | Peking University Third Hospital | | 2012-07-01 | 2012-07-30 |
| NCT00728507 | Tuberculosis | Drug: Rifapentine, Moxifloxacin, Pyrazinamide, Isoniazid|Drug: Isoniazid, Rifampin, Pyrazinamide, Ethambutol | Johns Hopkins University|Universidade Federal do Rio de Janeiro|Municipal Health Secretary of Rio de Janeiro|Helio Fraga Reference Center, Fiocruz | Phase 2 | 2009-11-01 | 2013-04-01 |
| NCT01191723 | Healthy | Drug: MAP0004|Drug: Inhaler Placebo|Drug: Moxifloxacin|Drug: Placebo Capsule | Allergan|MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan | Phase 1 | 2010-08-01 | 2013-12-09 |
| NCT00887276 | Community Acquired Pneumonia | Drug: Moxifloxacin|Drug: Ampicillin;Amoxicillin | University of Ulm|CAPNETZ Stiftung | Phase 4 | 2008-11-01 | 2014-12-16 |
| NCT00398411 | Hodgkin Disease|Non-Hodgkin Lymphoma|Multiple Myeloma|Bacteremia | Drug: moxifloxacin|Drug: placebo | University of Cologne | Phase 3 | 2006-10-01 | 2015-06-01 |
| NCT00840580 | Cataract Extraction | Drug: Moxifloxacin 0.5% ophthalmic solution (Vigamox)|Drug: Levofloxacin 0.5% ophthalmic solution (Cravit) | Alcon Research | Phase 4 | 2009-01-01 | 2012-07-19 |
